Similarly, in a study of 216 RyR2 variant-carrying CPVT patients, the risk of arrhythmic events was notably elevated in those prescribed β1-selective β-blockers compared to nadolol (HR 5.8, p = 0.001), with no significant differences observed between nadolol and propranolol [78]. Here, RYR2 is linked to catecholaminergic polymorphic ventricular tachycardia.